Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the immunisation protects at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine works by stimulating the mother’s body’s defences to generate protective antibodies, which are then passed to the foetus through the placenta. This mother-derived protection offers newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence suggesting that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if administered later in the third trimester.

• Nearly 85% protection when vaccinated four weeks before birth
• Antibodies from the mother passed through the placenta protect newborns from day one
• Protection possible with two-week gap before early delivery
• Vaccination in the third trimester still provides significant infant protection

Compelling evidence from recent research

The performance of the RSV vaccine administered during pregnancy has been confirmed through a comprehensive study undertaken in England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month period, providing robust and representative evidence of the vaccine’s real-world impact. The study’s findings have been supported by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The scope of this study gives healthcare professionals and expectant parents with assurance in the vaccine’s proven efficacy across different groups and contexts.

The results present a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the vast majority being infants whose mothers had not been given the vaccination. This clear distinction highlights the vaccine’s vital importance in reducing the risk of serious illness in newborns. The drop in hospital admissions above 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.

Study methodology and scope

The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospitalisations. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or small subgroups.

The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology measured practical outcomes rather than controlled laboratory conditions, providing practical evidence of how the vaccine performs when delivered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.

Understanding RSV and the risks

Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.

The infection triggers inflammation deep within the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe properly. Parents often witness their babies visibly struggling, their chests rising whilst they attempt to draw sufficient oxygen into their weakened respiratory system. Whilst most newborns improve through clinical support, a small but significant proportion perish from RSV-related complications annually, making immunisation programmes a vital health service objective for safeguarding the youngest and most vulnerable individuals in the population.

• RSV triggers inflammation in lungs, causing severe breathing difficulties in babies
• Approximately half of infants catch the virus during their first few months alive
• Symptoms range from minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
• More than 20,000 UK infants require serious hospital care for RSV annually
• Small numbers of babies succumb to RSV complications each year in the UK

Adoption rates and expert recommendations

Since the RSV vaccine programme began in 2024, health officials have emphasised the significance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that the timing is essential for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts recommend women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies through the placenta.

The communication from public health bodies remains clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This flexible approach recognises the practical demands of pregnancy whilst ensuring strong safeguarding for at-risk infants during their most critical early months when RSV poses the greatest risk of serious illness.

Regional disparities in immunisation

Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These regional differences reflect variations in healthcare infrastructure, communication strategies, and community involvement initiatives, though the overall statistics shows consistently strong protection regardless of geographical location.

• NHS trusts rolling out diverse outreach initiatives to reach women during pregnancy
• Geographic variations in vaccination coverage levels in different parts of England necessitate strategic intervention
• Local healthcare systems modifying schemes to suit specific population needs

Practical implications and parent viewpoints

The vaccine’s impressive effectiveness provides concrete gains for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the launch of this protective measure, the 80% drop in admissions means thousands of infants protected against critical disease. Parents no longer face the troubling prospect of seeing their babies gasping for air or labour to feed, symptoms that define critical RSV illness. The vaccine has substantially transformed the landscape of neonatal lung health, providing expectant mothers a proactive tool to safeguard their most vulnerable children during those crucial first weeks.

For families like that of Malachi, whose acute RSV infection caused profound brain damage, the vaccine’s availability carries significant emotional significance. His mother’s support of the jab highlights the life-altering consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such serious complications—hospitalisation, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to women in pregnancy navigating their third trimester, transforming what was once an inevitable seasonal threat into a manageable health risk.